专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2021108601A1 FORMULATIONS OF TERAMEPROCOL AND TEMOZOLOMIDE AND THEIR USE IN STIMULATION OF HUMORAL IMMUNITY IN TUMORS 审中-公开
公开(公告)号：WO2021108601A1
公开(公告)日：2021-06-03
申请号：PCT/US2020/062288
申请日：2020-11-25
申请人： THE JOHNS HOPKINS UNIVERSITY , ACADEMIA SINICA , NATIONAL CHIAO TUNG UNIVERSITY
发明人： HUANG, Ru Chih C. , CHUN, Jong Ho , LIN, Yu-Ling , LIANG, Yu-Chuan , LIAO, Kunag-Wen , JACKSON, Tiffany , MOLD, David
IPC分类号： A61K31/4188 , A61K31/495 , A61K47/02
摘要： The present invention provides novel pharmaceutical formulations comprising derivatives of NDGA, including M4N (tetra-0-methyl nordihydroguaiaretic acid) and temozolomide and their use in the inhibition and treatment of neoplastic diseases, including glioblastoma multiforme, lung and other cancers.

3. 发明申请

WO2017173022A1 IN VIVO AMELIORATION OF ENDOGENOUS ANTI-TUMOR AUTOANTIBODIES TARGETING SURFACE TUMOR ANTIGENS VIA LOW-DOSE P4N 审中-公开
标题翻译：通过低剂量P4N体内诱导表达肿瘤抗原的内源性抗肿瘤自体抗体
公开(公告)号：WO2017173022A1
公开(公告)日：2017-10-05
申请号：PCT/US2017/024905
申请日：2017-03-30
申请人： THE JOHNS HOPKINS UNIVERSITY , NATIONAL CHIAO TUNG UNIVERSITY
发明人： HUANG, Ru Chih C. , MOLD, David , JACKSON, Tiffany , LIN, Yu-Ling , LIAO, Kuang-Wen
IPC分类号： A61K31/435 , A61P35/00
摘要： In accordance with the present invention, the immunoregulatory activity of low doses of P 4 N was investigated. Unlike previously described antitumor drugs, low dose P 4 N, in doses of about 1 to 10 mg/kg, or at concentrations of about 10 to 100 nM, was surprisingly found to contribute to humoral immunity by raising the titers and activities of autoantibodies against GRP78 and F1F0 ATP synthase on the surface of CT26 cells, and inducing B cell proliferation and differentiation of plasma cells. Methods for inducing endogenous antitumor autoantibodies (EAA) in a subject having a neoplasia comprising administering to the subject an effective amount of the nordihydroguaiaretic acid (NDGA) derivative P4N, or salts, solvates and stereoisomers thereof, as well as methods for inducing B cell proliferation, inducing BAFF stimulated B cell proliferation, and suppressing or inhibition growth of a neoplasia are also provided.
摘要翻译：根据本发明，研究了低剂量的P N 4 N的免疫调节活性。与先前描述的抗肿瘤药物不同，以约1至10mg / kg的剂量或以约10至100nM的浓度的低剂量P 4 N令人惊讶地发现通过提高 CT26细胞表面抗GRP78和F1F0 ATP合酶自身抗体的滴度和活性，诱导B细胞增殖和分化浆细胞。在具有瘤形成的受试者中诱导内源性抗肿瘤自身抗体（EAA）的方法，包括给受试者施用有效量的去甲二氢愈创木酸（NDGA）衍生物P4N或其盐，溶剂化物和立体异构体，以及诱导B细胞增殖，诱导BAFF刺激的B细胞增殖，并且还提供了抑制或抑制瘤形成的生长。

4. 发明公开

EP3436008A1 IN VIVO AMELIORATION OF ENDOGENOUS ANTI-TUMOR AUTOANTIBODIES TARGETING SURFACE TUMOR ANTIGENS VIA LOW-DOSE P4N 审中-公开
公开(公告)号：EP3436008A1
公开(公告)日：2019-02-06
申请号：EP17776617.7
申请日：2017-03-30
申请人： The Johns Hopkins University , National Chiao Tung University
发明人： HUANG, Ru Chih C. , MOLD, David , JACKSON, Tiffany , LIN, Yu-Ling , LIAO, Kuang-Wen
IPC分类号： A61K31/435 , A61P35/00

5. 发明公开

EP2809308A1 COMPOSITIONS COMPRISING NDGA DERIVATIVES AND SORAFENIB AND THEIR USE IN TREATMENT OF CANCER 有权
标题翻译：组合物NDGA衍生物及其索拉非尼和癌症治疗
公开(公告)号：EP2809308A1
公开(公告)日：2014-12-10
申请号：EP13744007.9
申请日：2013-02-04
申请人： The Johns Hopkins University
发明人： HUANG, Ru Chih , RULAND, Christopher , LIANG, Yo-Chuan , CHUN, Jong Ho , MOLD, David
IPC分类号： A61K31/045 , A61K31/03 , A61K31/12 , A61P35/00
CPC分类号： A61K31/7016 , A61K31/05 , A61K31/09 , A61K31/44 , A61K45/06 , A61K2300/00
摘要： The present invention provides pharmaceutical compositions comprising derivatives of NDGA, including M4N (tetra-O-methyl nordihydroguaiaretic acid) and sorafenib and their use in the inhibition and treatment of neoplastic diseases, such as liver cancer, colon cancer, breast cancer, brain cancers and ovarian cancers, for example, in a subject. Compositions comprising derivatives of NDGA, including M4N, sorafenib and additional therapeutic agents are also provided.

6. 发明授权

EP2809308B1 COMPOSITIONS COMPRISING NDGA DERIVATIVES AND SORAFENIB AND THEIR USE IN TREATMENT OF CANCER 有权
公开(公告)号：EP2809308B1
公开(公告)日：2018-06-27
申请号：EP13744007.9
申请日：2013-02-04
申请人： The Johns Hopkins University
发明人： HUANG, Ru Chih , RULAND, Christopher , LIANG, Yu-Chuan , CHUN, Jong Ho , MOLD, David
IPC分类号： A61K31/045 , A61K31/03 , A61K31/12 , A61P35/00
CPC分类号： A61K31/7016 , A61K31/05 , A61K31/09 , A61K31/44 , A61K45/06 , A61K2300/00
摘要： The present invention provides pharmaceutical compositions comprising derivatives of NDGA, including M4N (tetra-O-methyl nordihydroguaiaretic acid) and sorafenib and their use in the inhibition and treatment of neoplastic diseases, such as liver cancer, colon cancer, breast cancer, brain cancers and ovarian cancers, for example, in a subject. Compositions comprising derivatives of NDGA, including M4N, sorafenib and additional therapeutic agents are also provided.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式